Human immunoglobulin G

Identification

Name
Human immunoglobulin G
Accession Number
DB00028
Description

Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Protein Structure
Db00028
Protein Chemical Formula
C6332H9826N1692O1980S42
Protein Average Weight
142682.3 Da
Sequences
>IGG1
PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
>IgA2
ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
HVNVSVVMAEVDGTCY
Download FASTA Format
Synonyms
  • Human IGG
  • Human immunoglobulin G
  • Human normal immunoglobulin
  • Immune globulin (human)
  • Immune globulin human
  • Immunoglobulin (human)
  • Immunoglobulin G (human)
  • Immunoglobulin G, human
  • IVIg

Pharmacology

Indication

IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.

Mechanism of action

IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.

TargetActionsOrganism
AHigh affinity immunoglobulin gamma Fc receptor I
antagonist
Humans
AHigh affinity immunoglobulin gamma Fc receptor IB
antagonist
Humans
ALow affinity immunoglobulin gamma Fc region receptor II-a
antagonist
Humans
ALow affinity immunoglobulin gamma Fc region receptor II-b
antagonist
Humans
ALow affinity immunoglobulin gamma Fc region receptor II-c
antagonist
Humans
ALow affinity immunoglobulin gamma Fc region receptor III-A
antagonist
Humans
ALow affinity immunoglobulin gamma Fc region receptor III-B
antagonist
Humans
AComplement C3
binder
Humans
AComplement C4-A
binder
Humans
AComplement C4-B
binder
Humans
AComplement C5
binder
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life

>20 hours (mammalian reticulocytes, in vitro).

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
  • Bacteria and protozoa
  • Various viruses
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abciximab.
AdalimumabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alirocumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).
Asfotase alfaThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asfotase alfa.
AtezolizumabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.
AvelumabThe risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Avelumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AscenivLiquid5 g/50mLIntravenousAdma Biologics, Inc.2019-04-01Not applicableUs
BivigamLiquid10 g/100mLIntravenousAdma Biologics, Inc.2013-01-21Not applicableUs
BivigamLiquid5 g/50mLIntravenousAdma Biologics, Inc.2013-01-21Not applicableUs
BivigamInjection, solution10 g/100mLIntravenousADMA Biologics, Inc2013-02-042021-09-30Us
BivigamInjection, solution1 g/10mLIntravenousKedrion Biopharma, Inc.2013-02-04Not applicableUs
BivigamInjection, solution5 g/50mLIntravenousADMA Biologics, Inc2013-02-042021-09-30Us
Carimune NanofilteredInjection, powder, lyophilized, for solution3 g/1IntravenousCsl Behring Ag1984-06-072009-01-06Us
Carimune NanofilteredInjection, powder, lyophilized, for solution12 g/1IntravenousCsl Behring Ag2009-02-102021-05-31Us
Carimune NanofilteredInjection, powder, lyophilized, for solution6 g/1IntravenousCsl Behring Ag2009-02-102021-05-31Us
CutaquigSolution2 gSubcutaneousOctapharma Pharmazeutika Produktionsges M B H2018-08-17Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Gammagard S/dHuman immunoglobulin G (10 g)Powder, for solutionIntravenousBaxalta Canada Corporation1997-08-22Not applicableCanada
Gammagard S/dHuman immunoglobulin G (5 g)Powder, for solutionIntravenousBaxalta Canada Corporation1997-08-22Not applicableCanada
HyqviaHuman immunoglobulin G (100 mg/1mL) + Hyaluronidase (human recombinant) (160 [USP'U]/1mL)SubcutaneousBaxalta US Inc.2014-09-12Not applicableUs
HyqviaHuman immunoglobulin G (100 mg/1mL) + Hyaluronidase (human recombinant) (160 [USP'U]/1mL)SubcutaneousBaxalta US Inc.2014-09-12Not applicableUs
HyqviaHuman immunoglobulin G (100 mg/1mL) + Hyaluronidase (human recombinant) (160 [USP'U]/1mL)SubcutaneousBaxalta US Inc.2014-09-12Not applicableUs
HyqviaHuman immunoglobulin G (100 mg/1mL) + Hyaluronidase (human recombinant) (160 [USP'U]/1mL)SubcutaneousBaxalta US Inc.2014-09-12Not applicableUs
HyqviaHuman immunoglobulin G (100 mg/1mL) + Hyaluronidase (human recombinant) (160 [USP'U]/1mL)SubcutaneousBaxalta US Inc.2014-09-12Not applicableUs
Iveegam Immuno 5000mg (iv)Human immunoglobulin G (5 g) + Water (100 ml)Kit; Liquid; Powder, for solutionIntravenousBaxter Ag1992-12-312008-12-23Canada

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
66Y330CJHS
CAS number
308067-58-5

References

Synthesis Reference

Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.

US4082734
General References
  1. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9. [PubMed:20970960]
  2. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  3. Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. [PubMed:16998749]
  4. Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. [PubMed:12032582]
UniProt
P01877
Genbank
J00221
PubChem Substance
46508774
RxNav
1426680
PharmGKB
PA164754884
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
AHFS Codes
  • 80:04.00 — Serums

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentAsperger's Disorder / Autism, Early Infantile / Autistic Disorder / PDD / Pervasive Developmental Disorder NOS1
4Active Not RecruitingTreatmentPediatric Acute-Onset Neuropsychiatric Syndrome / Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections1
4Active Not RecruitingTreatmentPrimary Immunodeficiency Diseases (PID)1
4CompletedPreventionAnti-Hepatitis A Antibody Levels in Heathy Subjects1
4CompletedPreventionBruton's agammaglobulinemia / Common Variable Immunodeficiency / Hyper IgM Syndrome / Hyper-IgM Syndrome / Primary Immune Deficiency Disorders (PIDD) / Wiskott-Aldrich Syndrome (WAS)1
4CompletedPreventionPrimary Immune Deficiency (PID) / Secondary Immune Deficiency1
4CompletedTreatmentAgammaglobulinemia / Common Variable Immunodeficiency1
4CompletedTreatmentCongenital Immunodeficiency3
4CompletedTreatmentEnd Stage Renal Disease (ESRD)1
4CompletedTreatmentErythroblastosis, Fetal / Hyperbilirubinemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alpha Therapeutic Corp.
  • American Red Cross
  • Baxter International Inc.
  • Biotest Pharmaceuticals
  • Cangene Corp.
  • CSL Behring LLC
  • Grifols SA
  • Massachusetts Public Health
  • Massbiologics
  • Medimmune Inc.
  • Novartis AG
  • Octapharma USA
  • Talecris Biotherapeutics
Dosage Forms
FormRouteStrength
LiquidIntravenous5 g/50mL
Injection, solutionIntravenous1 g/10mL
Injection, solutionIntravenous10 g/100mL
LiquidIntravenous10 g/100mL
Injection, powder, lyophilized, for solutionIntravenous12 g/1
Injection, powder, lyophilized, for solutionIntravenous3 g/1
Injection, powder, lyophilized, for solutionIntravenous6 g/1
SolutionSubcutaneous1 g
SolutionSubcutaneous1.65 g
SolutionSubcutaneous165 mg/1mL
SolutionSubcutaneous2 g
SolutionSubcutaneous3.3 g
SolutionSubcutaneous4 g
SolutionSubcutaneous8 g
Injection, solutionSubcutaneous200 mg/1mL
Injection, solutionIntravenous0.5 g/10mL
Injection, solutionIntravenous0.05 g/1mL
Injection, solutionIntravenous100 mg/ml
Injection, solutionIntravenous5 g/50mL
Injection, solutionIntravenous50 mg/ml
Injection, solutionIntramuscular0.165 g/1mL
LiquidIntramuscular16.5 %
SolutionIntramuscular18 %
SolutionIntramuscular
Injection, solutionIntravenous; Subcutaneous100 mg/1mL
KitIntravenous50 mg/1mL
Powder, for solutionIntravenous
Powder, for solutionIntravenous2.5 g
Powder, for solutionIntravenous
InjectionIntravenous; Subcutaneous10 g/100mL
SolutionIntravenous5 g/50mL
SolutionIntravenous5 g/100mL
LiquidIntramuscular
InjectionIntravenous1 g/1g
SolutionIntravenous; Subcutaneous10 g
Injection, solutionSubcutaneous200 mg/ml
LiquidSubcutaneous0.2 g/1mL
SolutionSubcutaneous200 mg
SolutionIntramuscular1500 unit
Injection, solutionSubcutaneous100 mg/ml
SolutionIntravenous; Subcutaneous
LiquidIntravenous
Kit; liquid; powder, for solutionIntravenous
SolutionIntravenous
SolutionIntravenous50 mg/1mL
SolutionIntravenous100 mg
SolutionIntravenous100 mg/1mL
LiquidIntravenous20 g/200mL
LiquidIntravenous40 g/400mL
SolutionIntravenous10 %
SolutionSubcutaneous160 mg/1mL
SolutionSubcutaneous160 mg
LiquidIntramuscular; Intravenous1500 [iU]/1mL
LiquidIntramuscular; Intravenous15000 [iU]/1mL
LiquidIntramuscular; Intravenous2500 [iU]/1mL
LiquidIntramuscular; Intravenous5000 [iU]/1mL
LiquidIntramuscular; Intravenous600 [iU]/1mL
InjectionIntramuscular; Intravenous1500 [iU]/1
InjectionIntramuscular; Intravenous15000 [iU]/1
InjectionIntramuscular; Intravenous2500 [iU]/1
InjectionIntramuscular; Intravenous5000 [iU]/1
SolutionSubcutaneous20 %
SolutionSubcutaneous200 mg/1mL
Prices
Unit descriptionCostUnit
Hypertet s-d 250 unit syringe324.23USD syringe
Hyperrab s-d vial224.07USD ml
Nabi-hb vial176.34USD ml
Hyperhep b s-d vial165.04USD ml
Hizentra 1 gram/5 ml vial30.24USD ml
Hizentra 2 gram/10 ml vial30.24USD ml
Hizentra 4 gram/20 ml vial30.24USD ml
Gamastan s-d vial24.44USD ml
Gammagard liquid 10% vial13.79USD ml
Gamunex 10% vial11.6USD ml
Immune globulin vial9.34USD ml
Flebogamma 5% vial4.84USD ml
Flebogamma dif 5% vial4.84USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
hydrophobicity-0.331Not Available
isoelectric point8.13Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.
Gene Name
FCGR1A
Uniprot ID
P12314
Uniprot Name
High affinity immunoglobulin gamma Fc receptor I
Molecular Weight
42631.525 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Immunoglobulin receptor activity
Specific Function
May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.
Gene Name
FCGR1B
Uniprot ID
Q92637
Uniprot Name
High affinity immunoglobulin gamma Fc receptor IB
Molecular Weight
32231.795 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Not Available
Specific Function
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized ...
Gene Name
FCGR2A
Uniprot ID
P12318
Uniprot Name
Low affinity immunoglobulin gamma Fc region receptor II-a
Molecular Weight
35000.42 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Not Available
Specific Function
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complex...
Gene Name
FCGR2B
Uniprot ID
P31994
Uniprot Name
Low affinity immunoglobulin gamma Fc region receptor II-b
Molecular Weight
34043.355 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane signaling receptor activity
Specific Function
Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulat...
Gene Name
FCGR2C
Uniprot ID
P31995
Uniprot Name
Low affinity immunoglobulin gamma Fc region receptor II-c
Molecular Weight
35577.96 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Not Available
Specific Function
Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as...
Gene Name
FCGR3A
Uniprot ID
P08637
Uniprot Name
Low affinity immunoglobulin gamma Fc region receptor III-A
Molecular Weight
29088.895 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Not Available
Specific Function
Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent...
Gene Name
FCGR3B
Uniprot ID
O75015
Uniprot Name
Low affinity immunoglobulin gamma Fc region receptor III-B
Molecular Weight
26215.64 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Receptor binding
Specific Function
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C...
Gene Name
C3
Uniprot ID
P01024
Uniprot Name
Complement C3
Molecular Weight
187146.73 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Endopeptidase inhibitor activity
Specific Function
Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances th...
Gene Name
C4A
Uniprot ID
P0C0L4
Uniprot Name
Complement C4-A
Molecular Weight
192783.805 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.
Specific Function
Carbohydrate binding
Gene Name
C4B
Uniprot ID
P0C0L5
Uniprot Name
Complement C4-B
Molecular Weight
192749.785 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Receptor binding
Specific Function
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C...
Gene Name
C5
Uniprot ID
P01031
Uniprot Name
Complement C5
Molecular Weight
188303.705 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465]

Drug created on June 13, 2005 07:24 / Updated on August 10, 2020 08:11

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates